HAEM5:Volunteer Assignments and Opportunities: Difference between revisions
| [unchecked revision] | [checked revision] |
No edit summary |
No edit summary |
||
| (138 intermediate revisions by 11 users not shown) | |||
| Line 1: | Line 1: | ||
Welcome! | Ian Welcome! | ||
'''A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.''' | |||
*For assignments, please see the "Author" column below (highlighted blue). | |||
*If empty (no name is present), please volunteer to create content for that disease! | |||
*If "PENDING" is present, the original author of that disease page is currently being contacted about revising the content. | |||
*To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest. | *To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest. | ||
*Note - NEW (No Prior) means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content added. | *Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content previously added. | ||
__TOC__ | |||
<br /> | <br /> | ||
{| class="wikitable" style="margin:auto" | {| class="wikitable sortable" style="margin:auto" | ||
|+<big>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues ( | |+<big>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th Edition) Content</big> | ||
|- | |- | ||
!Disease (5th Edition)!!Page Type!!Author (5th Edition) (Note: please indicate trainees in parentheses)!!Date Assigned to Author (5th Edition) | !Disease (5th Edition)!!Page Type!!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)!!Date Assigned to Author (5th Edition) | ||
!Target Completion Date (5th Edition)!!Content Status (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review (5th Edition)!!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | !Correlated Prior Disease Name (4th Edition) | ||
!Correlated Prior Author (4th Edition) | !Correlated Prior Author (4th Edition) | ||
| Line 16: | Line 25: | ||
!Prior Notes (4th Edition) | !Prior Notes (4th Edition) | ||
|- | |- | ||
|CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS) | | | ||
====CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)==== | |||
| | | | ||
----<br /> | ----<br /> | ||
| Line 46: | Line 56: | ||
----<br /> | ----<br /> | ||
|- | |- | ||
|[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease|| || || | |[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease||Meenakshi Mehrotra | ||
|4/8/24, email again in 9/29/25; Meenakshi confirmed om 9/30/25. | |||
| ||Pending|| ||Fabiola Quintero-Rivera (FQR)|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 53: | Line 65: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Clonal cytopenias of undetermined significance|Clonal cytopenias of undetermined significance]]||Disease|| || || | |[[HAEM5:Clonal cytopenias of undetermined significance|Clonal cytopenias of undetermined significance]]||Disease||Zejuan Li | ||
|10/3/2025 | |||
| ||Pending|| ||FQR|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 60: | Line 74: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease|| || || || || ||FQR|| || | |[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease||J . Reid||9/29/25|| || || ||FQR|| || | ||
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive | |Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive | ||
|Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | |Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | ||
| Line 67: | Line 81: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Chronic neutrophilic leukaemia|Chronic neutrophilic leukaemia]]||Disease|| | |[[HAEM5:Chronic neutrophilic leukaemia|Chronic neutrophilic leukaemia]]||Disease||PENDING | ||
| || || || ||FQR|| || | |||
|Chronic Neutrophilic Leukemia (CNL) | |Chronic Neutrophilic Leukemia (CNL) | ||
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine <nowiki>**</nowiki>contributed equally | |Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine <nowiki>**</nowiki>contributed equally | ||
| Line 74: | Line 89: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease|| | | |[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease||Daynna Wolff | ||
|10/14/25|| || || ||FQR|| || | |||
|Chronic Eosinophilic Leukemia, Not Otherwise Specified | |Chronic Eosinophilic Leukemia, Not Otherwise Specified | ||
|Chelsea D. Kramish; Daynna J.Wolff | |Chelsea D. Kramish; Daynna J.Wolff | ||
| Line 81: | Line 97: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease|| | |[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease|| | ||
| || || || ||FQR|| || | |||
|Polycythemia Vera (PV) | |Polycythemia Vera (PV) | ||
|Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center | |Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center | ||
| Line 88: | Line 105: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease|| || || | | |[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN | ||
|10/1/25|| ||Pending|| ||FQR|| || | |||
|Essential Thrombocythemia (ET) | |Essential Thrombocythemia (ET) | ||
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN | |Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN | ||
| Line 95: | Line 113: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Primary myelofibrosis|Primary myelofibrosis]]||Disease|| | |[[HAEM5:Primary myelofibrosis|Primary myelofibrosis]]||Disease||PENDING | ||
| || || || ||FQR|| || | |||
|Primary Myelofibrosis (PMF) | |Primary Myelofibrosis (PMF) | ||
|T. Niroshi Senaratne, UCLA | |T. Niroshi Senaratne, UCLA | ||
| Line 102: | Line 121: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Juvenile myelomonocytic leukaemia|Juvenile myelomonocytic leukaemia]]||Disease|| '''Sarah Rapisardo, PhD, FACMG''' | | |[[HAEM5:Juvenile myelomonocytic leukaemia|Juvenile myelomonocytic leukaemia]]||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |PENDING | ||
| || || || ||FQR|| || | |||
|Juvenile Myelomonocytic Leukemia (JMML) | |Juvenile Myelomonocytic Leukemia (JMML) | ||
|<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki> | |<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki> | ||
| Line 113: | Line 133: | ||
|FQR has emailed SR several times, last 4/20/22 | |FQR has emailed SR several times, last 4/20/22 | ||
|- | |- | ||
|[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease|| | !Disease (5th Edition) | ||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
|[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease||PENDING | |||
| || || || ||FQR|| || | |||
|Myeloproliferative Neoplasm (MPN), Unclassifiable | |Myeloproliferative Neoplasm (MPN), Unclassifiable | ||
|Thomas Lee, MD, PhD, University of California, Los Angeles | |Thomas Lee, MD, PhD, University of California, Los Angeles | ||
| Line 120: | Line 157: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Cutaneous mastocytosis|Cutaneous mastocytosis]]||Disease|| | |[[HAEM5:Cutaneous mastocytosis|Cutaneous mastocytosis]]||Disease||PENDING | ||
| || || || ||FQR|| || | |||
|Cutaneous Mastocytosis | |Cutaneous Mastocytosis | ||
|S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD | |S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD | ||
| Line 127: | Line 165: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Systemic mastocytosis|Systemic mastocytosis]]||Disease|| || || || || ||FQR|| || | |[[HAEM5:Systemic mastocytosis|Systemic mastocytosis]]||Disease||PENDING|| || || || ||FQR|| || | ||
|Systemic Mastocytosis | |Systemic Mastocytosis | ||
| | |Abdullah Osme, MD, University Hospitals Cleveland Medical Center, Case Western Reserve University Shashi Shetty, Ph.D. FACMG, FCCMG, University Hospitals Cleveland Medical Center, Case Western Reserve University | ||
|Complete | |Complete | ||
| | | | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Mast cell sarcoma|Mast cell sarcoma]]||Disease|| | |[[HAEM5:Mast cell sarcoma|Mast cell sarcoma]]||Disease||PENDING | ||
| || || || ||FQR|| || | |||
|Mast Cell Sarcoma | |Mast Cell Sarcoma | ||
|Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL | |Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL | ||
| Line 141: | Line 180: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Myelodysplastic neoplasm with low blasts and 5q deletion|Myelodysplastic neoplasm with low blasts and 5q deletion]]||Disease|| | |[[HAEM5:Myelodysplastic neoplasm with low blasts and 5q deletion|Myelodysplastic neoplasm with low blasts and 5q deletion]]||Disease||PENDING | ||
| || || || ||FQR|| || | |||
|Myelodysplastic Syndrome (MDS) with Isolated del(5q) | |Myelodysplastic Syndrome (MDS) with Isolated del(5q) | ||
|Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG | |Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG | ||
| Line 148: | Line 188: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease|| | |[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease|| | ||
| || || || ||FQR|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 155: | Line 196: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Myelodysplastic neoplasm with biallelic TP53 inactivation|Myelodysplastic neoplasm with biallelic TP53 inactivation]]||Disease||Eric McGinnis (assigned to new 5th edition page - FQR is this reviewed?)|| || || || ||FQR|| || | |[[HAEM5:Myelodysplastic neoplasm with biallelic TP53 inactivation|Myelodysplastic neoplasm with biallelic TP53 inactivation]]||Disease||Eric McGinnis (assigned to new 5th edition page - FQR is this reviewed?) YES fqr 9/29/25|| || || || ||FQR|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 176: | Line 217: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Myelodysplastic neoplasm with increased blasts|Myelodysplastic neoplasm with increased blasts]]||Disease|| | |[[HAEM5:Myelodysplastic neoplasm with increased blasts|Myelodysplastic neoplasm with increased blasts]]||Disease||PENDING | ||
| || || || ||FQR|| || | |||
|Myelodysplastic Syndrome (MDS) with Excess Blasts | |Myelodysplastic Syndrome (MDS) with Excess Blasts | ||
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | |Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | ||
| Line 183: | Line 225: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease|| | !Disease (5th Edition) | ||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
|[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease||PENDING | |||
| || || || ||FQR|| || | |||
|Refractory Cytopenia of Childhood | |Refractory Cytopenia of Childhood | ||
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | |Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | ||
| Line 190: | Line 249: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Childhood myelodysplastic neoplasm with increased blasts|Childhood myelodysplastic neoplasm with increased blasts]]||Disease|| | |[[HAEM5:Childhood myelodysplastic neoplasm with increased blasts|Childhood myelodysplastic neoplasm with increased blasts]]||Disease||PENDING | ||
| || || || ||FQR|| || | |||
|Refractory Cytopenia of Childhood | |Refractory Cytopenia of Childhood | ||
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | |Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | ||
| Line 197: | Line 257: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Chronic myelomonocytic leukaemia|Chronic myelomonocytic leukaemia]]||Disease|| | |[[HAEM5:Chronic myelomonocytic leukaemia|Chronic myelomonocytic leukaemia]]||Disease||PENDING | ||
| || || || ||FQR|| || | |||
|Chronic Myelomonocytic Leukemia (CMML) | |Chronic Myelomonocytic Leukemia (CMML) | ||
|Linsheng Zhang, MD, PhD | |Linsheng Zhang, MD, PhD | ||
| Line 204: | Line 265: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia|Myelodysplastic/myeloproliferative neoplasm with neutrophilia]]||Disease|| | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia|Myelodysplastic/myeloproliferative neoplasm with neutrophilia]]||Disease||PENDING | ||
| || || || ||FQR|| || | |||
|Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative | |Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative | ||
|Linsheng Zhang, MD, PhD | |Linsheng Zhang, MD, PhD | ||
| Line 211: | Line 273: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis]]||Disease|| | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis]]||Disease||PENDING | ||
| || || || ||FQR|| || | |||
|Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) | |Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) | ||
|Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine | |Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine | ||
| Line 218: | Line 281: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease|| | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease|| | ||
| || || || ||FQR|| || | |||
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable | |Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable | ||
|Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia | |Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia | ||
| Line 227: | Line 291: | ||
|[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]] | |[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]] | ||
|Disease | |Disease | ||
|Rabail Aslam, MD (trainee); | |||
Shashi Shetty, Ph.D. | |||
|7/1/24 | |||
| | | | ||
| | |Pending | ||
| | | | ||
|Jennelle Hodge (JH)/ Malini Sathanoori (MS) | |Jennelle Hodge (JH)/ Malini Sathanoori (MS) | ||
| Line 243: | Line 308: | ||
|[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]] | |[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]] | ||
|Disease | |Disease | ||
|Mayuri Shende (trainee); | |||
Scott Turner (mentor)<br /> | |||
|9/22/24 | |||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 259: | Line 325: | ||
|[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]] | |[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]] | ||
|Disease | |Disease | ||
|Mayuri Shende (trainee); | |||
Scott Turner (mentor)<br /> | |||
|9/22/24 | |||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 275: | Line 342: | ||
|[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]] | |[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]] | ||
|Disease | |Disease | ||
|Jennelle C. Hodge, PhD | |||
| | | | ||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 288: | Line 355: | ||
|02/24/2021-MS (re-review) | |02/24/2021-MS (re-review) | ||
| | | | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]] | |[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]] | ||
|Disease | |Disease | ||
|Jennelle C. Hodge, PhD | |||
| | | | ||
| | | | ||
| | |Complete | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 307: | Line 390: | ||
|[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]] | |[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]] | ||
|Disease | |Disease | ||
| | |Xinxiu Xu (trainee); | ||
| | Malini Sathanoori, Ph.D. | ||
|4/15/25 | |||
| | | | ||
| | | | ||
| Line 323: | Line 407: | ||
|[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]] | |[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]] | ||
|Disease | |Disease | ||
|Rabail Aslam, MD (trainee); | |||
Shashi Shetty, Ph.D. | |||
|7/1/24 | |||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 339: | Line 424: | ||
|[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]] | |[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]] | ||
|Disease | |Disease | ||
|Gordana Raca MD PhD, | |||
|9/8/25 | |||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 355: | Line 440: | ||
|[[HAEM5:Acute myeloid leukaemia with NUP98 rearrangement|Acute myeloid leukaemia with NUP98 rearrangement]] | |[[HAEM5:Acute myeloid leukaemia with NUP98 rearrangement|Acute myeloid leukaemia with NUP98 rearrangement]] | ||
|Disease | |Disease | ||
|Eric McGinnis, MD | |Eric McGinnis, MD; | ||
Fatma Al-Bulushi (trannee) | |||
|12/20/23 | |12/20/23 | ||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 378: | Line 464: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |emailed request on 7/16/24. No response as of 9/7/25. | ||
Prior author: Xinjie Xu, PhD, FACMG | |||
Open to new author | |||
|Acute Myeloid Leukemia (AML) with Mutated NPM1 | |Acute Myeloid Leukemia (AML) with Mutated NPM1 | ||
|Xinjie Xu, PhD, FACMG | |Xinjie Xu, PhD, FACMG | ||
|Complete | |Complete | ||
| | | | ||
|Add WHO reference | |Add WHO reference<br /> | ||
|- | |- | ||
|[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]] | |[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]] | ||
|Disease | |Disease | ||
| | |Xinxiu Xu (trainee); | ||
| | Malini Sathanoori, Ph.D. | ||
|4/15/25 | |||
| | | | ||
| | | | ||
| Line 410: | Line 500: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25 | ||
|Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes | |Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes | ||
|Fei Yang, MD, FACMG <br> Oregon Health & Science University | |Fei Yang, MD, FACMG <br> Oregon Health & Science University | ||
| Line 442: | Line 532: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |Prior author: Celeste Eno, PhD | ||
Open to new author | |||
|Acute Myeloid Leukemia (AML) with Minimal Differentiation | |Acute Myeloid Leukemia (AML) with Minimal Differentiation | ||
|Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles, Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine | |Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles, Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine | ||
| Line 448: | Line 540: | ||
| | | | ||
| | | | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]] | |[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]] | ||
|Disease | |Disease | ||
|Jennelle C. Hodge, PhD | |||
| | | | ||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 467: | Line 575: | ||
|[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]] | |[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]] | ||
|Disease | |Disease | ||
|Jennelle C. Hodge, PhD | |||
| | | | ||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 483: | Line 591: | ||
|[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]] | |[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]] | ||
|Disease | |Disease | ||
|Ashwini Yenamandra PhD FACMG | |||
|5/1/24 | |||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 506: | Line 614: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25 | ||
|Acute Myelomonocytic Leukemia | |Acute Myelomonocytic Leukemia | ||
|Fei Yang, MD, FACMG <br> Oregon Health & Science University | |Fei Yang, MD, FACMG <br> Oregon Health & Science University | ||
| Line 522: | Line 630: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25 | ||
|Acute Monoblastic and Monocytic Leukemia | |Acute Monoblastic and Monocytic Leukemia | ||
|Fei Yang, MD, FACMG <br> Oregon Health & Science University | |Fei Yang, MD, FACMG <br> Oregon Health & Science University | ||
| Line 531: | Line 639: | ||
|[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]] | |[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]] | ||
|Disease | |Disease | ||
|Ashwini Yenamandra PhD FACMG | |||
|5/1/24 | |||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 554: | Line 662: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25 | ||
|Acute Megakaryoblastic Leukemia (AMKL) | |Acute Megakaryoblastic Leukemia (AMKL) | ||
|Fei Yang, MD, FACMG <br> Oregon Health & Science University | |Fei Yang, MD, FACMG <br> Oregon Health & Science University | ||
| Line 563: | Line 671: | ||
|[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]] | |[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]] | ||
|Disease | |Disease | ||
|Yalda Naeini | |||
|6/11/24 | |||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 598: | Line 706: | ||
|[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]] | |[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]] | ||
|Disease | |Disease | ||
|Rabail Aslam, MD (trainee); | |||
Shashi Shetty, Ph.D. | |||
|7/1/24 | |||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 611: | Line 720: | ||
| | | | ||
|Check reference format | |Check reference format | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]] | |[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]] | ||
|Disease | |Disease | ||
|Malini Sathanoori, Ph.D. | |||
|12/6/24 | |||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 637: | Line 762: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |Prior author: | ||
Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO | |||
|MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome | |MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome | ||
|Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO | |Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO | ||
| Line 646: | Line 772: | ||
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRA rearrangement|Myeloid/lymphoid neoplasm with PDGFRA rearrangement]] | |[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRA rearrangement|Myeloid/lymphoid neoplasm with PDGFRA rearrangement]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 662: | Line 788: | ||
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRB rearrangement|Myeloid/lymphoid neoplasm with PDGFRB rearrangement]] | |[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRB rearrangement|Myeloid/lymphoid neoplasm with PDGFRB rearrangement]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 678: | Line 804: | ||
|[[HAEM5:Myeloid/lymphoid neoplasm with FGFR1 rearrangement|Myeloid/lymphoid neoplasm with FGFR1 rearrangement]] | |[[HAEM5:Myeloid/lymphoid neoplasm with FGFR1 rearrangement|Myeloid/lymphoid neoplasm with FGFR1 rearrangement]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 729: | Line 855: | ||
|[[HAEM5:Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion]] | |[[HAEM5:Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion]] | ||
|Disease | |Disease | ||
|Mayuri Shende (trainee); | |||
Scott Turner (mentor)<br /> | |||
|9/22/24 | |||
| | | | ||
| | |Pending | ||
| | | | ||
|FQR | |FQR | ||
| Line 745: | Line 872: | ||
|[[HAEM5:Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes]] | |[[HAEM5:Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes]] | ||
|Disease | |Disease | ||
|Rolando Garcia | |||
|2/7/2025 | |||
| | | | ||
| | |Pending | ||
| | | | ||
|FQR | |FQR | ||
| Line 761: | Line 888: | ||
|[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]] | |[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]] | ||
|Disease | |Disease | ||
|Tracy Tucker, PhD, FCCMG | |||
|4/6/24 | |||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 774: | Line 901: | ||
| | | | ||
| | | | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]] | |[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]] | ||
|Disease | |Disease | ||
|Tracy Tucker, PhD, FCCMG | |||
|4/6/24 | |||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |||
|JH_MS | |||
| | | | ||
| | | | ||
| Line 809: | Line 952: | ||
|[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]] | |[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]] | ||
|Disease | |Disease | ||
|Rabail Aslam, MD (trainee); | |||
Shashi Shetty, Ph.D. | |||
|7/1/24 | |||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 825: | Line 969: | ||
|[[HAEM5:Mixed-phenotype acute leukaemia, T/myeloid|Mixed-phenotype acute leukaemia, T/myeloid]] | |[[HAEM5:Mixed-phenotype acute leukaemia, T/myeloid|Mixed-phenotype acute leukaemia, T/myeloid]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 832: | Line 976: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |emailed 5/1/24 | ||
|Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified | |Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified | ||
|Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine | |Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine | ||
| Line 841: | Line 985: | ||
|[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]] | |[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]] | ||
|Disease | |Disease | ||
|Daynna Wolff, PhD | |||
|5/9/24 | |||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 873: | Line 1,017: | ||
|[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]] | |[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]] | ||
|Disease | |Disease | ||
|Rabail Aslam, MD (trainee); | |||
Shashi Shetty, Ph.D. | |||
|7/1/24 | |||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 887: | Line 1,032: | ||
|Check reference format | |Check reference format | ||
|- | |- | ||
|CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS) | !Disease (5th Edition) | ||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
| | |||
====CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS)==== | |||
| | | | ||
----<br /> | ----<br /> | ||
| Line 935: | Line 1,097: | ||
|[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]] | |[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]] | ||
|Disease | |Disease | ||
| | |Daynna Wolff | ||
| | |5/3/2025 | ||
| | |8/3/2025 | ||
| | |Pending | ||
| | | | ||
|GC | |GC | ||
| Line 962: | Line 1,124: | ||
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | |Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | ||
|Complete | |Complete | ||
|5/19/2022<br /> | |5/19/2022 Emailed 5/6/2025, no reply<br /> | ||
|Date completed by author: 04/28/2022 | |Date completed by author: 04/28/2022 | ||
|- | |- | ||
| Line 978: | Line 1,140: | ||
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | |Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | ||
|Complete | |Complete | ||
|5/19/2022<br /> | |5/19/2022 Emailed 5/6/2025, no reply<br /> | ||
|Date completed by author: 04/28/2022 | |Date completed by author: 04/28/2022 | ||
|- | |- | ||
| Line 999: | Line 1,161: | ||
|[[HAEM5:Interdigitating dendritic cell sarcoma|Interdigitating dendritic cell sarcoma]] | |[[HAEM5:Interdigitating dendritic cell sarcoma|Interdigitating dendritic cell sarcoma]] | ||
|Disease | |Disease | ||
|Muhammad Zulfiqar, MD | |||
|7/4/2025 | |||
|10/4/2025 | |||
|Pending | |||
| | | | ||
|GC | |||
|GC | |||
| | | | ||
| | | | ||
| Line 1,015: | Line 1,177: | ||
|[[HAEM5:Juvenile xanthogranuloma|Juvenile xanthogranuloma]] | |[[HAEM5:Juvenile xanthogranuloma|Juvenile xanthogranuloma]] | ||
|Disease | |Disease | ||
| | |Mayuri Shende (trainee); | ||
| | Scott Turner (mentor)<br /> | ||
| | |9/22/24 | ||
| | |12/22/24 Emailed 9/4/2025 to remind | ||
|Pending | |||
| | | | ||
|GC | |GC | ||
| Line 1,031: | Line 1,194: | ||
|[[HAEM5:Erdheim-Chester disease|Erdheim-Chester disease]] | |[[HAEM5:Erdheim-Chester disease|Erdheim-Chester disease]] | ||
|Disease | |Disease | ||
| | |Mayuri Shende (trainee); | ||
| | Scott Turner (mentor)<br /> | ||
| | |9/22/24 | ||
| | |12/22/24 Emailed 9/4/2025 to remind | ||
|Pending | |||
| | | | ||
|GC | |GC | ||
| Line 1,047: | Line 1,211: | ||
|[[HAEM5:Rosai-Dorfman Disease|Rosai-Dorfman Disease]] | |[[HAEM5:Rosai-Dorfman Disease|Rosai-Dorfman Disease]] | ||
|Disease | |Disease | ||
| | |Mayuri Shende (trainee); | ||
| | Scott Turner (mentor)<br /> | ||
| | |9/22/24 | ||
| | |12/22/24 Emailed 9/4/2025 to remind | ||
|Pending | |||
| | | | ||
|GC | |GC | ||
| Line 1,091: | Line 1,256: | ||
|Complete | |Complete | ||
|10/01/2021 | |10/01/2021 | ||
|Date completed by author: 10/01/2021 | |Date completed by author: 10/01/2021. Emailed both authors 5/1/2025, no reply. | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS) | | | ||
====CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)==== | |||
| | | | ||
----<br /> | ----<br /> | ||
| Line 1,125: | Line 1,307: | ||
|[[HAEM5:Reactive B-cell rich lymphoid proliferations that can mimic lymphoma|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma]] | |[[HAEM5:Reactive B-cell rich lymphoid proliferations that can mimic lymphoma|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma]] | ||
|Disease | |Disease | ||
| | |Muhammad Zulfiqar, MD | ||
| | |7/4/2025 | ||
| | |10/4/2025 Emailed 9/4/2025 to remind | ||
| | |Pending | ||
| | | | ||
|GC | |GC | ||
| Line 1,141: | Line 1,323: | ||
|[[HAEM5:IgG4-related disease|IgG4-related disease]] | |[[HAEM5:IgG4-related disease|IgG4-related disease]] | ||
|Disease | |Disease | ||
| | |Muhammad Zulfiqar, MD | ||
| | |7/4/2025 | ||
| | |10/4/2025 Emailed 9/4/2025 to remind | ||
| | |Pending | ||
| | | | ||
|GC | |GC | ||
| Line 1,200: | Line 1,382: | ||
|Sudha Arumugam, MD | |Sudha Arumugam, MD | ||
|Complete | |Complete | ||
|01/24/2022 | |01/24/2022. Emailed 5/1/2025, no response | ||
|Date completed by author: 01/24/2022 | |Date completed by author: 01/24/2022 | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]] | ||
|Disease | |Disease | ||
|To be covered in B-ALL, NOS | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | |Sumi Kitahara (SK) | ||
| | | | ||
| | | | ||
| Line 1,221: | Line 1,419: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]] | ||
|Disease | |Disease | ||
|Miguel Gonzalez Mancera, MD | |||
| | | | ||
| | | | ||
|Complete (pending review by SK) | |||
| | | | ||
| | |SK | ||
| | | | ||
| | | | ||
| Line 1,237: | Line 1,435: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]] | ||
|Disease | |Disease | ||
|Miguel Gonzalez Mancera, MD | |||
| | | | ||
| | | | ||
|Complete (pending review by SK) | |||
| | | | ||
| | |SK | ||
| | | | ||
| | | | ||
| Line 1,253: | Line 1,451: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]] | ||
|Disease | |Disease | ||
|Holli | |Holli Drendel, PhD | ||
|Nov 11/2025 | |||
| | | | ||
|Pending | |||
| | | | ||
| | |SK | ||
| | | | ||
| | | | ||
| Line 1,269: | Line 1,467: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]] | ||
|Disease | |Disease | ||
|Karin Miller, MD | |||
|10/9/2025 | |||
|12/5/2025 | |||
| | | | ||
| | | | ||
| | |SK | ||
| | | | ||
| | | | ||
| Line 1,285: | Line 1,483: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]] | ||
|Disease | |Disease | ||
| | |Mark G. Evans, MD | ||
| | |10/1/2025 | ||
| | |11/17/2025 | ||
| | |Complete (pending review by SK) | ||
| | |11/8/2025 | ||
| | |SK | ||
| | |Pending | ||
| | | | ||
|B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | |B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | ||
| Line 1,301: | Line 1,499: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]] | ||
|Disease | |Disease | ||
|Gokce A. Toruner, MD, PhD | |||
|10/9/2025 | |||
|11/5/2025 | |||
|Pending | |||
| | | | ||
| | |SK | ||
| | | | ||
| | | | ||
| Line 1,317: | Line 1,515: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]] | ||
|Disease | |Disease | ||
|Gokce A. Toruner, MD, PhD | |||
|10/8/2025 | |||
|12/1/2025 | |||
|Pending | |||
| | | | ||
| | |SK | ||
| | | | ||
| | | | ||
| Line 1,333: | Line 1,531: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features]] | ||
|Disease | |Disease | ||
|Lei Zhang, PhD | |||
Michelle Fan (trainee) | |||
|10/10/2025 | |||
|12/22/2025 | |||
|Pending | |||
| | | | ||
| | |SK | ||
| | | | ||
| | | | ||
| Line 1,349: | Line 1,548: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]] | ||
|Disease | |Disease | ||
|Miguel Gonzalez Mancera, MD | |||
|10/1/2025 | |||
| | | | ||
|Pending | |||
| | | | ||
| | |SK | ||
| | | | ||
| | | | ||
| Line 1,365: | Line 1,564: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]] | ||
|Disease | |Disease | ||
|Miguel Gonzalez Mancera, MD | |||
|10/1/2025 | |||
| | | | ||
|Pending | |||
| | | | ||
| | |SK | ||
| | | | ||
| | | | ||
| Line 1,381: | Line 1,580: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion]] | ||
|Disease | |Disease | ||
|Aiko Otsubo, PhD | |||
|10/10/2025 | |||
|11/24/2025 | |||
|Complete (pending SK review) | |||
|11/11/2025 | |||
|SK | |||
|Pending | |||
| | | | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 1,397: | Line 1,596: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations]] | ||
|Disease | |Disease | ||
|Lei Zhang, PhD | |||
|10/10/2025 | |||
|12/22/2025 | |||
|Pending | |||
| | | | ||
| | |SK | ||
| | | | ||
| | | | ||
| Line 1,412: | Line 1,611: | ||
|- | |- | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma, NOS|B-lymphoblastic leukaemia/lymphoma, NOS]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma, NOS|B-lymphoblastic leukaemia/lymphoma, NOS]] | ||
|Disease | |Disease | ||
|Karin Miller, MD | |||
|10/9/2025 | |||
|11/24/2025 | |||
|Pending | |||
| | |||
|SK | |||
| | | | ||
| | | | ||
| Line 1,418: | Line 1,623: | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | |- | ||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|RESOLVE 4th edition ALL-Related NON-WHO entities content | |RESOLVE 4th edition ALL-Related NON-WHO entities content | ||
|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 | |B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 | ||
B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6 | |||
Resolve Non-WHO entities | B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements | ||
| | |||
B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions | |||
B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19) | |||
B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11) | |||
|ISSUE- FIX | |||
Resolve Non-WHO entities | |||
| | |||
| | | | ||
| | | | ||
| Line 1,446: | Line 1,676: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease|| || | | !Disease (5th Edition) | ||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty | |||
| ||9/4/2025 sent E-mail reminder|| || ||Shivani Golem (SG) | |||
| || | | || | ||
|Monoclonal B-cell Lymphocytosis | |Monoclonal B-cell Lymphocytosis | ||
|Tsigab Bahta Hagos (trainee) / Shashirekha Shetty | |Tsigab Bahta Hagos (trainee) / Shashirekha Shetty | ||
|PENDING | |PENDING, 4/30/2024 | ||
| | | | ||
|Assigned 12/19/2022 with completion date of 1/19/2023 | |Assigned 12/19/2022 with completion date of 1/19/2023 | ||
|- | |- | ||
|[[HAEM5:Chronic lymphocytic leukaemia/small lymphocytic lymphoma|Chronic lymphocytic leukaemia/small lymphocytic lymphoma]]||Disease||Jaime Nagy, PhD, University of Iowa | |[[HAEM5:Chronic lymphocytic leukaemia/small lymphocytic lymphoma|Chronic lymphocytic leukaemia/small lymphocytic lymphoma]]||Disease||Jaime Nagy, PhD, University of Iowa, | ||
Renee Eigsti, MD, Pathology Services of Kalamazoo | Renee Eigsti, MD, Pathology Services of Kalamazoo, | ||
Honey Reddi, PhD, Belay Diagnostics | Honey Reddi, PhD, Belay Diagnostics | ||
| || ||Complete | | || ||Complete|| ||SG|| || | ||
|Already converted to 5th edition | |Already converted to 5th edition | ||
|Jamie Nagy, PhD, University of Iowa Honey Reddi, PhD | |Jamie Nagy, PhD, University of Iowa Honey Reddi, PhD | ||
| Line 1,466: | Line 1,713: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease|| || || | | |[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease||Michael Lack, MD, KUMC (trainee); | ||
Shivani Golem | |||
|7/16/24||9/4/2025 sent E-mail reminder||PENDING|| ||SG|| ||Need new author to update latest content. Prior author cannot update the page. | |||
|Hairy Cell Leukemia | |Hairy Cell Leukemia | ||
|Snehal Patel, MD, PhD | |Snehal Patel, MD, PhD | ||
| | |Pending WHO 5th e. July 2024 | ||
| | | | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease|| || || | | |[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease||Madhu Pantrangi | ||
|4/15/25|| ||9/4/2025 sent E-mail reminder|| ||SG|| ||Need new author to update latest content. Prior author cannot update the page. | |||
|Splenic Marginal Zone Lymphoma | |Splenic Marginal Zone Lymphoma | ||
|Snehal Patel, MD, PhD | |Snehal Patel, MD, PhD | ||
| Line 1,480: | Line 1,730: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease|| | |[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease|| | ||
| || || || ||SG|| ||Need new author to update latest content. Prior author cannot update the page. | |||
|Splenic Diffuse Red Pulp Small B-cell Lymphoma | |Splenic Diffuse Red Pulp Small B-cell Lymphoma | ||
|Snehal Patel, MD, PhD | |Snehal Patel, MD, PhD | ||
| Line 1,496: | Line 1,747: | ||
|SG | |SG | ||
| | | | ||
| | |Need new author to update latest content. Prior author cannot update the page. | ||
|Hairy Cell Leukemia Variant | |Hairy Cell Leukemia Variant | ||
|Snehal Patel, MD, PhD | |Snehal Patel, MD, PhD | ||
| Line 1,507: | Line 1,758: | ||
| | | | ||
| | | | ||
| | |Sent e-mail to prev authors no reply | ||
| | | | ||
| | | | ||
|SG | |SG | ||
| | | | ||
| | |Email sent to request to update 2024 | ||
|(1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia | |(1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia | ||
|(1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI) | |(1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI) | ||
| Line 1,523: | Line 1,774: | ||
| | | | ||
| | | | ||
| | |Sent e-mail to prev authors no reply | ||
| | | | ||
| | | | ||
|SG | |SG | ||
| | | | ||
| | |Email sent to request to update 2024 | ||
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) | |Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) | ||
|Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG* | |Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG* | ||
| Line 1,539: | Line 1,790: | ||
|[[HAEM5:Primary cutaneous marginal zone lymphoma|Primary cutaneous marginal zone lymphoma]] | |[[HAEM5:Primary cutaneous marginal zone lymphoma|Primary cutaneous marginal zone lymphoma]] | ||
|Disease | |Disease | ||
|Molly Walkenhorst | |||
| | | | ||
| | |9/4/2025 sent E-mail reminder | ||
| | | | ||
| | | | ||
| Line 1,548: | Line 1,799: | ||
| | | | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|Molly Walkenhorst, DO and Shivani Golem, PhD, FACMG | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| | |- | ||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]] | |[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]] | ||
|Disease | |Disease | ||
|Andrew Ly | |||
| | | | ||
| | |9/4/2025 sent E-mail reminder | ||
| | | | ||
| | | | ||
| Line 1,578: | Line 1,845: | ||
|SG | |SG | ||
| | | | ||
| | |Need new author to update latest content. Prior authors cannot update the page. | ||
|Paediatric Nodal Marginal Zone Lymphoma | |Paediatric Nodal Marginal Zone Lymphoma | ||
|* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD | |* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD | ||
|Complete | |Complete; Need new author to update latest content. Primary author cannot update the page. | ||
|11/11/2020 | |11/11/2020 | ||
| | | | ||
| Line 1,589: | Line 1,856: | ||
|Rachel D. Burnside, PhD, MBA, FACMGG | |Rachel D. Burnside, PhD, MBA, FACMGG | ||
|7/28/2023 | |7/28/2023 | ||
| | |9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024 | ||
|Pending | |Pending | ||
| | | | ||
| Line 1,605: | Line 1,872: | ||
|Rachel D. Burnside, PhD, MBA, FACMGG | |Rachel D. Burnside, PhD, MBA, FACMGG | ||
|7/28/2023 | |7/28/2023 | ||
| | |9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024 | ||
|Pending | |Pending | ||
| | | | ||
| Line 1,619: | Line 1,886: | ||
|[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]] | |[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]] | ||
|Disease | |Disease | ||
|Rachel D. Burnside, PhD, MBA, FACMGG | |||
| | | | ||
| | |9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024 | ||
| | | | ||
| | | | ||
|SG | |SG | ||
| | | | ||
| | |Need new author to update latest content. Prior authors cannot update the page. | ||
|Paediatric-Type Follicular Lymphoma | |Paediatric-Type Follicular Lymphoma | ||
|*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG | |*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG | ||
|Complete | |Complete; Need new author to update latest content. Primary author cannot update the page. | ||
|8/16/2020 | |8/16/2020 | ||
| | | | ||
| Line 1,637: | Line 1,904: | ||
|Rachel D. Burnside, PhD, MBA, FACMGG | |Rachel D. Burnside, PhD, MBA, FACMGG | ||
|7/28/2023 | |7/28/2023 | ||
| | |9/4/2025 sent email reminder; Last E-mail to Dr. Burnside no reply 7/17/ | ||
|Pending | |Pending | ||
| | | | ||
| Line 1,651: | Line 1,918: | ||
|[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]] | |[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]] | ||
|Disease | |Disease | ||
|Linlin Gao | |||
| | | | ||
| | |9/4/2025 Sent E-mail to remind | ||
| | | | ||
| | | | ||
| Line 1,683: | Line 1,950: | ||
|[[HAEM5:Mantle cell lymphoma|Mantle cell lymphoma]] | |[[HAEM5:Mantle cell lymphoma|Mantle cell lymphoma]] | ||
|Disease | |Disease | ||
|PENDING | |||
| | | | ||
| | |9/4/2025 set E-mail reminder | ||
| | | | ||
| | | | ||
| Line 1,692: | Line 1,959: | ||
| | | | ||
|Mantle Cell Lymphoma | |Mantle Cell Lymphoma | ||
| | |Mahsa Khanlari, MD and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas | ||
|Pending | |Pending | ||
| | | | ||
| Line 1,699: | Line 1,966: | ||
|[[HAEM5:Leukaemic non-nodal mantle cell lymphoma|Leukaemic non-nodal mantle cell lymphoma]] | |[[HAEM5:Leukaemic non-nodal mantle cell lymphoma|Leukaemic non-nodal mantle cell lymphoma]] | ||
|Disease | |Disease | ||
|Farhan Sami | |||
| | | | ||
| | |9/4/2025 sent E-mail reminder | ||
| | | | ||
| | | | ||
| Line 1,708: | Line 1,975: | ||
| | | | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|Farhan Sami, MD and Shivani Golem, PhD, FACMG | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| | |- | ||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Transformations of indolent B-cell lymphomas|Transformations of indolent B-cell lymphomas]] | |[[HAEM5:Transformations of indolent B-cell lymphomas|Transformations of indolent B-cell lymphomas]] | ||
|Disease | |Disease | ||
|Farhan Sami | |||
| | | | ||
| | |9/4/2025 sent E-mail reminder | ||
| | | | ||
| | | | ||
| Line 1,724: | Line 2,007: | ||
|Include content on chronic myelomonocytic leukemia in transformation and refractory anaemia with excess blasts in transformation | |Include content on chronic myelomonocytic leukemia in transformation and refractory anaemia with excess blasts in transformation | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| | |Farhan Sami, MD and Shivani Golem, PhD, FACMG | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease|| | |[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease|| | ||
| || || || ||GC|| || | |||
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified | |Diffuse Large B-cell Lymphoma, Not Otherwise Specified | ||
|Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center | |Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center | ||
| Line 1,743: | Line 2,027: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease|| || | | |[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland | ||
|5/6/2025||8/6/2025 Emailed 9/4/2025 to remind|| || ||GC|| || | |||
|High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | |High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | ||
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland | |Kate Berry, MBBS, BBus (Hons), Pathology Queensland | ||
| Line 1,750: | Line 2,035: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease|| | |[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease|| | ||
| || || || ||GC|| || | |||
|ALK-Positive Large B-cell Lymphoma | |ALK-Positive Large B-cell Lymphoma | ||
|Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) | |Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) | ||
| | | | ||
| | | | ||
|Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23 | |Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23 | ||
|- | |- | ||
|[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease|| | |[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease|| | ||
| || || || ||GC|| || | |||
|Large B-cell Lymphoma with IRF4 Rearrangement | |Large B-cell Lymphoma with IRF4 Rearrangement | ||
|Afia Hasnain, MBBS, PhD | |Afia Hasnain, MBBS, PhD | ||
|Complete | |Complete | ||
|5/26/2021 | |5/26/2021. Emailed 5/7//2025, no reply | ||
| | | | ||
|- | |- | ||
|[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease|| | |[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease|| | ||
| || || || ||GC|| || | |||
|Burkitt-Like Lymphoma with 11q Aberration | |Burkitt-Like Lymphoma with 11q Aberration | ||
|Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | |Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | ||
| | |Complete | ||
|27/01/2022 | |27/01/2022 Emailed 5/7//2025, no reply | ||
| | | | ||
|- | |- | ||
| Line 1,778: | Line 2,066: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease|| || || | | |[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease||Fnu Monika (trainee); | ||
Andrew Siref as mentor | |||
|3/22/24|| ||Pending|| ||GC|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 1,792: | Line 2,082: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease|| | !Disease (5th Edition) | ||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
|[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease|| | |||
| || || || ||GC|| ||Note: previously a subset DLBCL assoc with chronic inflam | |||
|Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior) | |Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 1,806: | Line 2,113: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease|| | |[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease|| | ||
| || || || ||GC|| || | |||
|Plasmablastic Lymphoma | |Plasmablastic Lymphoma | ||
|Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | |Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | ||
| Line 1,813: | Line 2,121: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease|| || | |[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease||Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital | ||
|6/28/2025 | |||
|9/28/2025 Emailed 9/4/2025 to remind.|| || ||GC|| || | |||
|(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS | |(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS | ||
|(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital | |(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital | ||
| Line 1,827: | Line 2,137: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease|| || | |[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland | ||
|5/6/2025 | |||
|8/6/2025 Emailed 9/4/2025 to remind | |||
| || ||GC|| || | |||
|Intravascular Large B-cell Lymphoma | |Intravascular Large B-cell Lymphoma | ||
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy | |Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy | ||
| Line 1,848: | Line 2,161: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease|| | |[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease|| | ||
| || || || ||GC|| || | |||
|High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS) | |High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS) | ||
|Aiko Otsubo, PhD, Indiana University, Holli Drendel | |Aiko Otsubo, PhD, Indiana University, Holli Drendel | ||
|Complete | |Complete | ||
|16/11/2021 | |16/11/2021 Emailed 5/6/2025, no reply | ||
| | | | ||
|- | |- | ||
|Burkitt lymphoma||Disease|| | |[[HAEM5:Burkitt lymphoma|Burkitt lymphoma]]||Disease|| | ||
| || || || ||GC|| || | |||
|Burkitt Lymphoma | |Burkitt Lymphoma | ||
|Becky Leung, MBBS (Hons), BSc, Pathology Queensland | |Becky Leung, MBBS (Hons), BSc, Pathology Queensland | ||
|Complete | |Complete | ||
|28/06/2021 | |28/06/2021 Emailed 5/6/2025, no reply | ||
| | | | ||
|- | |- | ||
|Primary effusion lymphoma||Disease|| || || || || ||GC|| || | !Disease (5th Edition) | ||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
|[[HAEM5:Primary effusion lymphoma|Primary effusion lymphoma]]||Disease|| || || || || ||GC|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 1,869: | Line 2,200: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| || | |[[HAEM5:KSHV/HHV8-positive diffuse large B-cell lymphoma|KSHV/HHV8-positive diffuse large B-cell lymphoma]]||Disease|| || || || || ||GC|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 1,876: | Line 2,207: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| || | |[[HAEM5:KSHV/HHV8-positive germinotropic lymphoproliferative disorder|KSHV/HHV8-positive germinotropic lymphoproliferative disorder]]||Disease|| || || || || ||GC|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 1,883: | Line 2,214: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Hyperplasias arising in immune deficiency/dysregulation||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others")|| || || || ||GC|| || | |[[HAEM5:Hyperplasias arising in immune deficiency/dysregulation|Hyperplasias arising in immune deficiency/dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others"). "Non-Destructive Post-Transplant Lymphoproliferative Disorders" was a HAME4 page but no content. What are "among others" from HAEM4 to see if we need to pull prior content into 5th edition page.|| || || || ||GC|| || | ||
| | | | ||
| | | | ||
| Line 1,890: | Line 2,221: | ||
| | | | ||
|- | |- | ||
|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||FIX ISSUE! (on 5th edition page instructions say "This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders]]. | |[[HAEM5:Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders]]. | ||
Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others)" | Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others)" | ||
| || || || ||GC|| || | | || || || ||GC|| || | ||
| Line 1,899: | Line 2,230: | ||
| | | | ||
|- | |- | ||
|EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| || | |[[HAEM5:EBV-positive mucocutaneous ulcer|EBV-positive mucocutaneous ulcer]]||Disease|| || || || || ||GC|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 1,906: | Line 2,237: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Lymphomas arising in immune deficiency / dysregulation||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing monomorphic PTLD, classic HL PTLD, lymphomas assoc with HIV infection, among others"|| || || || ||GC|| || | |[[HAEM5:Lymphomas arising in immune deficiency / dysregulation|Lymphomas arising in immune deficiency / dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing monomorphic PTLD, classic HL PTLD, lymphomas assoc with HIV infection, among others"|| || || || ||GC|| || | ||
| | | | ||
| | | | ||
| Line 1,913: | Line 2,244: | ||
| | | | ||
|- | |- | ||
|Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease||FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]")|| || || || ||GC|| || | |[[HAEM5:Inborn error of immunity-associated lymphoid proliferations and lymphomas|Inborn error of immunity-associated lymphoid proliferations and lymphomas]]||Disease||FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]") - last link name above is not a known page in haem4 or haem5.|| || || || ||GC|| || | ||
| | | | ||
| | | | ||
| Line 1,920: | Line 2,251: | ||
| | | | ||
|- | |- | ||
|Classic Hodgkin lymphoma||Disease|| || || || ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma | |[[HAEM5:Classic Hodgkin lymphoma|Classic Hodgkin lymphoma]]||Disease||Xiaolin Hu | ||
|5/7/2025 | |||
|8/7/2025 Reminder email sent 9/4/2025|| || | |||
|GC|| ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma | |||
|(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma | |(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma | ||
|(1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez | |(1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez | ||
| Line 1,928: | Line 2,261: | ||
| | | | ||
|- | |- | ||
|Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || | |[[HAEM5:Nodular lymphocyte predominant Hodgkin lymphoma|Nodular lymphocyte predominant Hodgkin lymphoma]]||Disease||Muhammad Zulfiqar, MD | ||
|7/4/2025 | |||
|10/4/2025 Reminder email sent 9/4/2025||Pending|| ||GC|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 1,935: | Line 2,270: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Cold agglutinin disease | !Disease (5th Edition) | ||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
|[[HAEM5:Cold agglutinin disease|Cold agglutinin disease]] | |||
|Disease | |Disease | ||
| | | | ||
| Line 1,951: | Line 2,302: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| || | |[[HAEM5:IgM monoclonal gammopathy of undetermined significance|IgM monoclonal gammopathy of undetermined significance]]||Disease|| || || || || ||SG|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 1,958: | Line 2,309: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| || | |[[HAEM5:Non-IgM monoclonal gammopathy of undetermined significance|Non-IgM monoclonal gammopathy of undetermined significance]]||Disease|| || || || || ||SG|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 1,965: | Line 2,316: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG | |[[HAEM5:Monoclonal gammopathy of renal significance|Monoclonal gammopathy of renal significance]]||Disease|| || || || || ||SG | ||
| || | | || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 1,973: | Line 2,324: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Immunoglobulin-related (AL) amyloidosis||Disease|| | |[[HAEM5:Immunoglobulin-related (AL) amyloidosis|Immunoglobulin-related (AL) amyloidosis]]||Disease|| | ||
| || || || ||SG | |||
| || | | || | ||
|Primary Amyloidosis | |Primary Amyloidosis | ||
| Line 1,981: | Line 2,333: | ||
| | | | ||
|- | |- | ||
|Monoclonal immunoglobulin deposition disease||Disease|| | |[[HAEM5:Monoclonal immunoglobulin deposition disease|Monoclonal immunoglobulin deposition disease]]||Disease|| | ||
| || || || ||SG | |||
| || | | || | ||
|Light Chain and Heavy Chain Deposition Disease | |Light Chain and Heavy Chain Deposition Disease | ||
| Line 1,989: | Line 2,342: | ||
| | | | ||
|- | |- | ||
|Mu heavy chain disease||Disease|| || || || || ||SG | |[[HAEM5:Mu heavy chain disease|Mu heavy chain disease]]||Disease|| || || || || ||SG | ||
| || | | || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 1,997: | Line 2,350: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Gamma heavy chain disease||Disease|| | |[[HAEM5:Gamma heavy chain disease|Gamma heavy chain disease]]||Disease|| | ||
| || || || ||SG | |||
| || | | || | ||
|Gamma Heavy Chain Disease | |Gamma Heavy Chain Disease | ||
| Line 2,005: | Line 2,359: | ||
| | | | ||
|- | |- | ||
|Alpha heavy chain disease||Disease|| || || || || ||SG | |[[HAEM5:Alpha heavy chain disease|Alpha heavy chain disease]]||Disease|| || || || || ||SG | ||
| || | | || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,013: | Line 2,367: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Plasmacytoma||Disease|| || || || | | |[[HAEM5:Plasmacytoma|Plasmacytoma]]||Disease|| | ||
| || || || | |||
|SG | |SG | ||
| || | | ||author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga) | ||
|NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang | |NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,022: | Line 2,377: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Plasma cell myeloma / multiple myeloma||Disease|| || || || ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page | |[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||Huan Mo; | ||
Zhenya Tang | |||
|4/14/25||7/14/25 | |||
9/4/2025 Sent E-mail reminder to Dr. Tang | |||
|Pending|| ||SG | |||
| ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page | |||
|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants | |(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants | ||
|(1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG | |(1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG | ||
| Line 2,030: | Line 2,389: | ||
| | | | ||
|- | |- | ||
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease|| || || || | |[[HAEM5:Plasma cell neoplasms with associated paraneoplastic syndrome|Plasma cell neoplasms with associated paraneoplastic syndrome]]||Disease||PENDING | ||
| ||9/4/2025 E-mail sent to Dr. Senaratne | |||
| || | |||
|SG | |SG | ||
| || | | ||Note: author needs to include POEMS, TEMPI, and look for AESOP content | ||
|(1) POEMS Syndrome + (2) TEMPI Syndrome | |(1) POEMS Syndrome + (2) TEMPI Syndrome | ||
|(1 and 2) Sohini Anand, MBBS Tharanga Niroshini Senaratne, PhD | |(1 and 2) Sohini Anand, MBBS Tharanga Niroshini Senaratne, PhD | ||
| Line 2,039: | Line 2,400: | ||
| | | | ||
|- | |- | ||
| | |Disease (5th Edition) | ||
| | |Page Type | ||
|Author (5th Edition) (Note: please indicate trainees in parenthesis) | |||
| | |Date Assigned to Author (5th Edition) | ||
|Target Completion Date (5th Edition) | |||
| | |Content Status (5th Edition) (Pending or Complete) | ||
|Date Completed by Author (5th Edition) | |||
| | |Associate Editor | ||
|Date of Last Editor Review (5th Edition) | |||
| | |Notes (5th Edition) | ||
|Correlated Prior Disease Name (4th Edition) | |||
| | |Correlated Prior Author (4th Edition) | ||
|Prior Content Status (4th Edition) (Pending or Complete) | |||
| | |Prior Date of Last Editor Review (4th Edition) | ||
- | |Prior Notes (4th Edition) | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
| | !Notes (5th Edition) | ||
!Correlated Prior Disease Name (4th Edition) | |||
| | !Correlated Prior Author (4th Edition) | ||
-- | !Prior Content Status (4th Edition)(Pending or Complete) | ||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
| colspan="15" | | |||
====CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)==== | |||
|- | |- | ||
|Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK) | |[[HAEM5:Kikuchi-Fujimoto disease|Kikuchi-Fujimoto disease]]||Disease|| Sumire Kitahara, MD|| || || '''Complete'''|| 11/6/2025||Sumi Kitahara (SK) | ||
| || | | || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,077: | Line 2,443: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Autoimmune lymphoproliferative syndrome||Disease|| || || | |[[HAEM5:Autoimmune lymphoproliferative syndrome|Autoimmune lymphoproliferative syndrome]]||Disease||Aviv Oren, MD (trainee); | ||
Karin Miller, MD | |||
|3/25/2024 | |||
| ||Pending | |||
| ||SK|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,084: | Line 2,454: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK|| || | |[[HAEM5:Indolent T-lymphoblastic proliferation|Indolent T-lymphoblastic proliferation]]||Disease|| || || || || ||SK|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,091: | Line 2,461: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || || | |[[HAEM5:T-lymphoblastic leukaemia / lymphoma, NOS|T-lymphoblastic leukaemia / lymphoma, NOS]]||Disease|| || || || || ||SK|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,098: | Line 2,468: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Early T-precursor lymphoblastic leukaemia / lymphoma | |[[HAEM5:Early T-precursor lymphoblastic leukaemia / lymphoma|Early T-precursor lymphoblastic leukaemia / lymphoma]] | ||
|Disease | |Disease | ||
|Fei Yang, MD | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | |SK | ||
| | | | ||
| | | | ||
| Line 2,114: | Line 2,484: | ||
| | | | ||
|- | |- | ||
|T-prolymphocytic leukaemia | |[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]] | ||
|Disease | |Disease | ||
| | |Parastou Tizro, MD; | ||
| | Celeste Eno, PhD; Sumire Kitahara, MD | ||
| | |9/23/2025 | ||
| | |11/4/2025 | ||
| | |'''Complete''' | ||
|11/4/2025 | |||
|SK | |SK | ||
| | |11/6/2025 | ||
| | | | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,130: | Line 2,501: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|T-large granular lymphocytic leukaemia||Disease|| || | | |[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Nicolas LaScala (trainee); | ||
Michelle Don, MD, MS | |||
|9/24/2025 | |||
|12/9/2025 | |||
|Pending | |||
| ||SK|| || | |||
|T-cell Large Granular Lymphocytic Leukemia | |T-cell Large Granular Lymphocytic Leukemia | ||
|Michelle Don, MD, MS | |Michelle Don, MD, MS | ||
| Line 2,137: | Line 2,513: | ||
| | | | ||
|- | |- | ||
|NK-large granular lymphocytic leukaemia||Disease|| || || | |[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Hailee St. Louis (trainee); | ||
Michelle Don, MD, MS | |||
|9/24/2025 | |||
|12/9/2025 | |||
|'''Complete''' | |||
| 12/17/2025||SK|| 1/6/2026|| | |||
|Chronic Lymphoproliferative Disorder of NK Cells | |Chronic Lymphoproliferative Disorder of NK Cells | ||
|Michelle Don, MD | |Michelle Don, MD | ||
| Line 2,144: | Line 2,525: | ||
| | | | ||
|- | |- | ||
|Adult T-cell leukaemia/lymphoma||Disease|| || | | |[[HAEM5:Adult T-cell leukaemia/lymphoma|Adult T-cell leukaemia/lymphoma]]||Disease||Sumire Kitahara, MD | ||
|9/23/2025 | |||
|11/30/2025 | |||
|Pending | |||
| ||SK|| || | |||
|Adult T-cell Leukemia/Lymphoma | |Adult T-cell Leukemia/Lymphoma | ||
|Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center | |Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center | ||
| Line 2,151: | Line 2,536: | ||
| | | | ||
|- | |- | ||
|Sezary syndrome||Disease|| || | |[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD | ||
|3/22/2024 | |||
|follow-up needed | |||
| || ||SK|| || | |||
|Sézary Syndrome | |Sézary Syndrome | ||
|Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina | |Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina | ||
| Line 2,158: | Line 2,546: | ||
| | | | ||
|- | |- | ||
|Aggressive NK-cell leukaemia||Disease|| || || | |[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||Shashirekha Shetty, PhD | ||
|10/15/2025||1/19/2026 | |||
|Pending | |||
| ||SK|| || | |||
|Aggressive NK-cell Leukemia | |Aggressive NK-cell Leukemia | ||
|Shanelle De Lancy, MD, Shashirekha Shetty, PhD | |Shanelle De Lancy, MD, Shashirekha Shetty, PhD | ||
| Line 2,165: | Line 2,556: | ||
| | | | ||
|- | |- | ||
|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || | !Disease (5th Edition) | ||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Ian King, PhD | |||
|1/6/2026 | |||
| 2/3/2026|| | |||
| ||SK|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,172: | Line 2,582: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || | |[[HAEM5:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder]]||Disease||Ahmed Eladely (trainee); | ||
Andrew Siref, MD | |||
|10/14/2025 | |||
|11/24/2025 | |||
|'''Complete''' | |||
| 12/29/2025||SK|| 1/6/2026|| | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,179: | Line 2,595: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Mycosis fungoides||Disease|| || | |[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD | ||
|3/22/2024 | |||
|follow-up needed|| || ||SK|| || | |||
|Mycosis Fungoides | |Mycosis Fungoides | ||
|Jane Scribner, MD and Daynna J. Wolff, PhD | |Jane Scribner, MD and Daynna J. Wolff, PhD | ||
| Line 2,186: | Line 2,604: | ||
| | | | ||
|- | |- | ||
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || | | |[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis]]||Disease||Rabail Aslam, MD (fellow); | ||
Shashirekha Shetty, PhD | |||
|7/1/2024 | |||
|follow-up needed | |||
| | |||
| ||SK|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,193: | Line 2,616: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease|| || || | |[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||Rabail Aslam, MD (fellow); | ||
Shashirekha Shetty, PhD | |||
|7/1/2024||follow-up needed | |||
| | |||
| ||SK|| || | |||
|Primary Cutaneous Anaplastic Large Cell Lymphoma | |Primary Cutaneous Anaplastic Large Cell Lymphoma | ||
|Theresa Spivey, MD, Shashirekha Shetty, PhD | |Theresa Spivey, MD, Shashirekha Shetty, PhD | ||
| Line 2,200: | Line 2,627: | ||
| | | | ||
|- | |- | ||
|Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || | |[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Ian King, PhD | ||
Katelyn Swanson, DO (trainee) | |||
|11/19/2025 | |||
|12/19/2025 | |||
|'''Complete''' | |||
| 1/6/2026||SK|| 1/6/2026|| | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,207: | Line 2,639: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || | | |[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee); | ||
Sumire Kitahara, MD | |||
|6/30/2024 | |||
|11/9/2025 | |||
|Pending | |||
| ||SK|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,214: | Line 2,651: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || | | |[[HAEM5:Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma]]||Disease||Ahmed Eladely (trainee); | ||
Andrew Siref, MD | |||
|10/14/2025||11/24/2025 | |||
|'''Complete''' | |||
| 12/29/2025||SK|| 1/6/2026|| | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,221: | Line 2,663: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| || | |[[HAEM5:Primary cutaneous peripheral T-cell lymphoma, NOS|Primary cutaneous peripheral T-cell lymphoma, NOS]]||Disease|| || || || || ||SK|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,228: | Line 2,670: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease|| | !Disease (5th Edition) | ||
| | !Page Type | ||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
|[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease|| | |||
| || || || ||SK|| || | |||
|Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract | |||
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | |Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | ||
| | |Pending | ||
| | | | ||
| | | | ||
|- | |- | ||
|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK|| || | |[[HAEM5:Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract]]||Disease|| || || || || ||SK|| || | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
|- | |- | ||
|Enteropathy-associated T-cell lymphoma||Disease|| || || | |[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee); | ||
| | Andrew Siref, MD | ||
|10/14/2025 | |||
| ||Pending|| ||SK|| || | |||
|Enteropathy-Associated T-cell Lymphoma | |||
|*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD | |*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD | ||
| | |Complete | ||
| | |1/21/2021 | ||
| | | | ||
|- | |- | ||
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease|| || || | |[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee); | ||
| | Andrew Siref, MD | ||
|10/14/2025 | |||
| ||Pending|| ||SK|| || | |||
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma | |||
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | |Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | ||
|Pending | |||
| | | | ||
| | | | ||
|- | |||
|[[HAEM5:Intestinal T-cell lymphoma, NOS|Intestinal T-cell lymphoma, NOS]]||Disease|| | |||
| || || || ||SK|| || | |||
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS) | |||
|Derick Okwan MD, PhD (Stanford) Sumire Kitahara MD (Cedars-Sinai) | |||
|Complete | |||
|9/26/2022 | |||
| | | | ||
|- | |- | ||
| | |[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Forough Sargolzaeiaval (trainee); | ||
| | Michelle Don, MD, MS | ||
| | |9/24/2025 | ||
| | |11/9/2025 | ||
|'''Complete''' | |||
|12/17/2025 | |||
|SK||1/6/2026|| | |||
|Hepatosplenic T-cell Lymphoma | |||
|Michelle Don, MD, MS | |||
|Complete | |||
|1/21/2021 | |||
| | | | ||
|- | |||
|[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee); | |||
Sumire Kitahara, MD | |||
|6/6/24|| || | |||
| ||SK|| || | |||
|Anaplastic Large Cell Lymphoma, ALK-Positive | |||
|Miguel Gonzalez Mancera, MD | |||
Sumire Kitahara, MD | |||
Cedars-Sinai, Los Angeles, CA | |||
|Complete | |||
|09/23/2022 | |||
| | | | ||
|- | |- | ||
| | |[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee); | ||
| | Sumire Kitahara, MD | ||
| | |6/6/24|| || | ||
| | | ||SK|| || | ||
| | |Anaplastic Large Cell Lymphoma, ALK-Negative | ||
|Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA | |||
|Complete | |||
|09/23/2022 | |||
| | | | ||
|- | |- | ||
| | |[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||Lynne Abruzzo, MD, PhD | ||
| | |9/22/2025 | ||
| | |1/1/2026 | ||
| | |Pending|| ||SK|| || | ||
|Breast Implant-Associated Anaplastic Large Cell Lymphoma | |||
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center | |||
|Pending | |||
| | | | ||
| | | | ||
|- | |- | ||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
| | |[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023 | ||
| | |follow-up needed | ||
| | | || ||SK|| ||prior authors not available | ||
| | |Angioimmunoblastic T-cell Lymphoma | ||
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG | |||
|Pending | |||
| | | | ||
| | | | ||
|- | |- | ||
|Nodal TFH cell lymphoma, | |[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023 | ||
|follow-up needed | |||
| || ||SK|| || | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|Nodal TFH cell lymphoma, follicular-type||Disease|| || | | |NEW (No Prior) | ||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |- | ||
|Nodal TFH cell lymphoma, NOS||Disease|| | |[[HAEM5:Nodal TFH cell lymphoma, NOS|Nodal TFH cell lymphoma, NOS]]||Disease|| | ||
| | | || || || ||SK|| || | ||
|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype | |||
|Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD | |Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD | ||
| | |Pending | ||
| | | | ||
| | | | ||
|- | |- | ||
|Peripheral T-cell lymphoma, NOS||Disease|| || | | |[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD | ||
| | |10/14/2025 | ||
| | |12/3/2025 | ||
| | |Pending | ||
| | | ||SK|| || | ||
| | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
|EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || | | |[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee); | ||
| | Andrew Siref, MD | ||
| | |10/14/2025|| ||Pending|| ||SK|| || | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
|Extranodal NK/T-cell lymphoma||Disease|| || || | |[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Maryam Mehdiopour Dalivand (trainee); Ian King, PhD | ||
| | |1/6/2026 | ||
| | | 2/3/2026||Pending | ||
| | | ||SK|| || | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
|Severe mosquito bite allergy||Disease|| || || || || ||SK|| || | |[[HAEM5:Severe mosquito bite allergy|Severe mosquito bite allergy]]||Disease|| || || || || ||SK|| || | ||
| | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |||
|[[HAEM5:Hydroa vacciniforme lymphoproliferative disorder|Hydroa vacciniforme lymphoproliferative disorder]]||Disease|| || || || || ||SK|| || | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |||
|[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD | |||
|3/25/2024 | |||
| 11/17/2025||Pending | |||
| ||SK|| || | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |||
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD | |||
|3/25/2024 | |||
| 11/17/2025||Pending | |||
| ||SK|| ||prior authors not available | |||
|Systemic EBV-Positive T-cell Lymphoma of Childhood | |||
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA | |||
|Complete | |||
|11/21/2021 | |||
| | | | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
| | | | ||
====CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)==== | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
----<br /> | |||
| | | | ||
----<br /> | ----<br /> | ||
| Line 2,391: | Line 2,930: | ||
----<br /> | ----<br /> | ||
|- | |- | ||
|Follicular dendritic cell sarcoma | |[[HAEM5:Follicular dendritic cell sarcoma|Follicular dendritic cell sarcoma]] | ||
|Disease | |Disease | ||
| | | | ||
| Line 2,401: | Line 2,940: | ||
| | | | ||
| | | | ||
| | |Follicular Dendritic Cell Sarcoma | ||
|Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG | |Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG | ||
| | |?Pending | ||
| | | | ||
| | | | ||
|- | |- | ||
|EBV-positive inflammatory follicular dendritic cell sarcoma | |[[HAEM5:EBV-positive inflammatory follicular dendritic cell sarcoma|EBV-positive inflammatory follicular dendritic cell sarcoma]] | ||
|Disease | |Disease | ||
| | | | ||
| Line 2,417: | Line 2,956: | ||
| | | | ||
| | | | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
|- | |- | ||
|Fibroblastic reticular cell tumour | |[[HAEM5:Fibroblastic reticular cell tumour|Fibroblastic reticular cell tumour]] | ||
|Disease | |Disease | ||
| | | | ||
| Line 2,431: | Line 2,970: | ||
| | | | ||
|GC | |GC | ||
| | |||
| | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |||
|[[HAEM5:Intranodal palisaded myofibroblastoma|Intranodal palisaded myofibroblastoma]] | |||
|Disease | |||
| | | | ||
| | | | ||
| Line 2,436: | Line 2,985: | ||
| | | | ||
| | | | ||
|GC | |||
| | | | ||
| | | | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
| | |[[HAEM5:Littoral cell angioma|Littoral cell angioma]] | ||
|Disease | |Disease | ||
| | | | ||
| Line 2,449: | Line 3,004: | ||
| | | | ||
| | | | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
|- | |- | ||
| | |[[HAEM5:Splenic hamartoma|Splenic hamartoma]] | ||
|Disease | |Disease | ||
| | | | ||
| Line 2,465: | Line 3,020: | ||
| | | | ||
| | | | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
|- | |- | ||
| | |[[HAEM5:Sclerosing angiomatoid nodular transformation (SANT) of spleen|Sclerosing angiomatoid nodular transformation (SANT) of spleen]] | ||
|Disease | |Disease | ||
| | | | ||
| Line 2,481: | Line 3,036: | ||
| | | | ||
| | | | ||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
| | | | ||
====CHAPTER 7 (GENETIC TUMOUR SYNDROMES)==== | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
| | | | ||
----<br /> | |||
----<br /> | |||
| | | | ||
----<br /> | ----<br /> | ||
| Line 2,533: | Line 3,089: | ||
----<br /> | ----<br /> | ||
|- | |- | ||
|Fanconi anaemia||Disease|| || || || || | | |[[HAEM5:Fanconi anaemia|Fanconi anaemia]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| | |N/A||N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
|N/A | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
|Bloom syndrome||Disease|| || || || || | |[[HAEM5:Bloom syndrome|Bloom syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
|N/A | |||
|N/A | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |- | ||
|Ataxia-telangiectasia syndrome||Disease|| || || || || || | |[[HAEM5:Ataxia-telangiectasia syndrome|Ataxia-telangiectasia syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]]||N/A||N/A||N/A||N/A||N/A||N/A||N/A | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
|- | |- | ||
|RASopathies||Disease|| || || || || ||NA|| || | |[[HAEM5:RASopathies|RASopathies]]||Disease|| || || || || ||NA|| || | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
|} | |} | ||